LOS ANGELES (BUSINESS WIRE) Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone (Clinicatrials.gov identifier NCT02187991) in metastatic hormone receptor positive (HR+) and.
Soligenix (NASDAQ:SNGX – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations. Risk & Volatility Soligenix has a beta of 1.74, indicating […]
Soligenix (NASDAQ:SNGX – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation. Profitability This table compares Soligenix and Puma Biotechnology’s net margins, […]
A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone have a history of invasive breast cancer. And .
A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone have a history of invasive breast cancer. And .